CD80/CD86-targeted CAR-T cells have been generated to reverse the inhibitory CTLA4-CD86/CD86 signals and prevent the survival of B cell malignancies and other tumors including NSCLC (128). Here, CD86 is linked to non-small cell lung carcinoma.